TCGA-CQ-5331-01A-02R-1873-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.750
- INTERFERON_GAMMA_RESPONSE+0.630
- ALLOGRAFT_REJECTION+0.530
- IL6_JAK_STAT3_SIGNALING+0.490
- INFLAMMATORY_RESPONSE+0.400
- MYC_TARGETS_V2+0.370
- COMPLEMENT+0.340
- PI3K_AKT_MTOR_SIGNALING+0.330
- MYC_TARGETS_V1+0.270
- MTORC1_SIGNALING+0.230
Top 10 suppressed
- MYOGENESIS-0.390
- ANGIOGENESIS-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
- HEDGEHOG_SIGNALING-0.320
- WNT_BETA_CATENIN_SIGNALING-0.270
- HYPOXIA-0.240
- GLYCOLYSIS-0.220
- PANCREAS_BETA_CELLS-0.200
- NOTCH_SIGNALING-0.170
- ESTROGEN_RESPONSE_EARLY-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518312 | — | D | 0.835 |
| 2 | TCGA-CV-6938-01A-11R-1915-07 | — | — | 0.819 |
| 3 | SRR25043627 | — | — | 0.819 |
| 4 | SRR8518156 | — | D | 0.816 |
| 5 | SAMN03290949 | — | — | 0.813 |
| 6 | TCGA-A8-A08P-01A-11R-A00Z-07 | — | C | 0.811 |
| 7 | SRR35579807 | — | C | 0.805 |
| 8 | MNG1225 | — | — | 0.803 |
| 9 | a88a1582-88b8-4e7e-9baf-09279b49a492 | — | — | 0.801 |
| 10 | TCGA-E7-A7XN-01A-11R-A352-07 | — | — | 0.801 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.750 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.630 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.330 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |